EMBARGOED: CAR-T not cost-effective as second-line therapy for diffuse large B-cell lymphoma at current prices, study finds
EMBARGOED: December 4, 2023, 5PM EST
Contact:
Nicole Oliverio, Dana-Farber Cancer Institute
617-257-0454, nicole_oliverio@dfci.harvard.edu
CAR-T not cost-effective as second-line therapy for diffuse large B-cell lymphoma at current prices, study finds
RESEARCH SUMMARY
Study Title: Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression
Publication: Annals of Internal Medicine, Click here for link
Dana-Farber Cancer Institute authors include: Amar H. Kelkar, MD, MPH (first author); Edward R. Scheffer Cliff, MBBS, MPH; Caron A. Jacobson, MD; Gregory A. Abel, MD, MPH; Corey Cutler, MD, MPH (senior author); and Robert Redd, MS.
Summary: Chimeric ...









